Key Events This Week
27 Jul: Stock rises 1.82% amid broad market gains
28 Jul: Sharp open interest surge of 14.5% despite Sensex dip
29 Jul: Open interest climbs 15.2%, Mojo Grade upgraded to Buy
30 Jul: Q1 FY27 results reveal strong revenue growth but margin pressures
31 Jul: Intraday low hit at Rs.2,445.45 amid heavy selling and 45.8% open interest surge
27 July 2026: Positive Start Amid Broad Market Rally
Mankind Pharma began the week on a strong note, closing at Rs.2,551.05, up 1.82% on the day. This outpaced the Sensex’s 1.05% gain, reflecting positive investor sentiment. The volume was moderate at 3,482 shares, supporting the price advance. The broader market rally provided a favourable backdrop, with the stock trading comfortably above key moving averages, signalling sustained medium-term strength.
28 July 2026: Surge in Open Interest Despite Market Headwinds
On 28 July, the stock surged further by 2.63% to Rs.2,618.15, reaching the week’s high. This price rise occurred despite the Sensex declining 0.14%, indicating relative strength. Notably, open interest in Mankind Pharma’s derivatives jumped 14.48% to 14,556 contracts, accompanied by a futures volume of 7,374 contracts and a combined futures and options notional value exceeding ₹12,106 crores. This surge suggests fresh capital inflows and active repositioning by traders anticipating significant price movements.
Investor participation intensified, with delivery volume soaring 153.37% above the five-day average, underscoring growing conviction. The stock traded near its 52-week high of Rs.2,674, maintaining a bullish technical posture despite a slight price dip the following day.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
29 July 2026: Mixed Price Action Amid Rising Open Interest and Mojo Upgrade
The stock retreated 0.98% to Rs.2,592.55 on 29 July, underperforming the Sensex’s 1.02% gain. Despite this, open interest expanded by 15.2% to 16,744 contracts, signalling continued active positioning. Futures volume rose to 9,095 contracts, with combined derivatives value around ₹10,095 crores. Delivery volume increased 28.43%, indicating sustained investor interest.
MarketsMOJO upgraded Mankind Pharma’s Mojo Grade from Hold to Buy on 29 July, citing strong fundamentals including a return on capital employed (ROCE) of 20.79%, robust debt servicing ratios, and expanding operating margins of 27.01%. The upgrade was supported by positive financial trends and improved technical indicators, including bullish daily moving averages and a weekly MACD signal.
Despite a slight price pullback, the stock remained near its 52-week high, trading just 4.17% below the peak, reflecting resilience amid sector volatility.
30 July 2026: Quarterly Results Highlight Revenue Growth Amid Margin Pressures
Mankind Pharma reported strong revenue growth for Q1 FY27, though margin pressures were evident. The company’s operating profit to net sales ratio stood at 27.01%, reflecting operational efficiency despite cost challenges. The stock closed at Rs.2,576.95, down 0.60%, continuing a modest decline from the previous day. Technical momentum shifted positively, with MarketsMOJO upgrading the technical grade to bullish, supported by daily moving averages and Bollinger Bands.
However, some oscillators such as the Know Sure Thing (KST) indicator showed mild bearishness on weekly charts, suggesting short-term caution. The stock’s relative strength remained robust, outperforming the Sensex over multiple timeframes, including a year-to-date gain of 18.04% versus the Sensex’s 8.88% decline.
Thinking about Mankind Pharma Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
31 July 2026: Sharp Intraday Decline Amid Volatile Trading and Record Open Interest
The final trading day saw Mankind Pharma’s shares plunge 4.15% to close at Rs.2,469.90, hitting an intraday low of Rs.2,445.45, a 5.06% drop from the previous close. This marked the third consecutive day of losses, with a cumulative decline of 6.11%. The stock underperformed the Pharmaceuticals & Biotechnology sector, which gained 0.76%, and the Sensex, which rose 0.39%.
Open interest surged dramatically by 45.82% to 26,432 contracts, accompanied by a hefty volume of 50,844 contracts traded. The derivatives notional value reached approximately ₹53,455 lakhs, with options contributing ₹27,639 crores, indicating intense market activity and repositioning amid volatile price action.
Technical indicators showed the stock trading below its 5-day, 20-day, and 50-day moving averages, signalling short-term weakness, though it remained above longer-term 100-day and 200-day averages. The weighted average price volatility was elevated at 6.23%, reflecting unsettled market conditions and profit-taking pressures.
Delivery volume dipped slightly by 0.47%, suggesting reduced investor participation in the cash segment despite heightened derivatives activity. This divergence points to tactical positioning by traders, possibly hedging or speculating on further volatility.
Weekly Price Performance Comparison
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-27 | Rs.2,551.05 | +1.82% | 36,207.16 | +1.05% |
| 2026-07-28 | Rs.2,618.15 | +2.63% | 36,155.32 | -0.14% |
| 2026-07-29 | Rs.2,592.55 | -0.98% | 36,524.95 | +1.02% |
| 2026-07-30 | Rs.2,576.95 | -0.60% | 36,541.96 | +0.05% |
| 2026-07-31 | Rs.2,469.90 | -4.15% | 36,684.83 | +0.39% |
Key Takeaways
Positive Signals: The stock demonstrated resilience by trading near its 52-week high for much of the week and maintaining levels above key long-term moving averages. The significant upgrades in Mojo Score and Grade to Buy reflect improved fundamentals, including strong ROCE, manageable leverage, and expanding operating margins. The surge in open interest on multiple days indicates active market participation and anticipation of directional moves, supported by robust delivery volumes on key sessions.
Cautionary Signals: Despite strong derivatives activity, the stock underperformed the Sensex over the week, declining 1.42% versus a 2.39% gain in the benchmark. The sharp intraday drop on 31 July and the breach of short-term moving averages signal near-term weakness and profit-taking. Elevated volatility and mixed technical indicators, such as mildly bearish KST and monthly MACD, suggest that investors should remain vigilant amid potential consolidation or correction phases.
Conclusion
Mankind Pharma Ltd’s week was characterised by heightened derivatives market activity and mixed price action. While the stock showed technical strength and fundamental improvements, including a Mojo Grade upgrade to Buy, it faced short-term selling pressure culminating in a notable intraday low on the final trading day. The divergence between strong open interest growth and price softness highlights a complex market environment where both bullish and cautious sentiments coexist.
Investors should monitor open interest trends, volume patterns, and technical indicators closely to discern the stock’s next directional move. The company’s solid financial metrics and market position provide a foundation for medium-term optimism, but near-term volatility and sector dynamics warrant a balanced approach.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
